The importance of long-term follow-up post CAR-T cell therapy
Take part in Dr. Tobias Menne, Consultant Hematologist, from the UK were he shares guidance on the long-term care of CAR T-cell therapy patients, highlighting structured follow-up and individualized support strategies. His approach underscores the importance of proactive planning to optimize patient outcomes over time.
Early CAR T-patient identification in 2L DLBCL – The UK experience
Take part in short interviwes with Dr Robin Sanderson, hematologist at King´s College Hospital in London, UK, where he shares his experiences in treating patients with DLBCL in 2L, including his thoughts on patient identification, the importance of early referral, as well as what is important when it comes to the collaboration between referring clinics and treating clinics.
(The film clips are approx. 2.5 minutes long)
Cost-effectiveness analysis of YESCARTA® (axicabtagene ciloleucel) in 2L DLBCL in Sweden
During EHA 2024, Viktor Hedlöf Kanje, Market Access Lead at Gilead, presented
a Swedish cost-effectiveness analysis of YESCARTA® (axicabtagene ciloleucel) in 2L DLBCL. Listen to the results of the analysis in the interview with Viktor.
(video about 2 min).
SE-TEC-0040 | 10/2025
